Genfit SA Sponsored ADR Stock

$3.61

5.99% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US3722791098

Symbol

GNFT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Genfit SA Sponsored ADR Stock price

$3.61

-1.93 34.84% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.23 5.99%

ISIN

US3722791098

Symbol

GNFT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$195.9m

Enterprise Value

$172.9m

Net debt

$-23.0m

Cash

$95.9m

Shares outstanding

50.0m

Valuation (TTM | estimate)

P/E

90.25 | negative

P/S

2.36 | 2.04

EV/Sales

2.08 | 1.80

EV/FCF

10.12

P/B

2.22

Financial Health

Equity Ratio

45.70%

Return on Equity

2.18%

ROCE

4.23%

ROIC

5.15%

Debt/Equity

0.90

Financials (TTM | estimate)

Revenue

$83.1m | $96.1m

EBITDA

$5.8m | $33.0m

EBIT

$3.8m

Net Income

$1.8m | $-4.0m

Free Cash Flow

$17.1m

Growth (TTM | estimate)

Revenue

85.83% | 15.58%

EBITDA

119.83% | 466.25%

EBIT

112.10%

Net Income

105.23% | -325.42%

Free Cash Flow

125.35%

Margin (TTM | estimate)

Gross

97.11%

EBITDA

7.00% | 34.30%

EBIT

4.55%

Net

2.12% | -4.15%

Free Cash Flow

20.54%

EPS

$0.04

FCF per Share

$0.34

Short interest

0.08%

Employees

169.00

Rev per Employee

$490.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Genfit SA Sponsored ADR Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Genfit SA Sponsored ADR forecast:

12x Buy

92%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Genfit SA Sponsored ADR forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Genfit SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	83 83	86% 86% 100%
- Direct Costs	2.40 2.40	6% 6% 3%
Gross Profit	81 81	91% 91% 97%
- Selling and Administrative Expenses	10 10	4% 4% 13%
- Research and Development Expense	40 40	4% 4% 48%
EBITDA	5.82 5.82	120% 120% 7%
- Depreciation and Amortization	2.04 2.04	7% 7% 2%
EBIT (Operating Income) EBIT	3.78 3.78	112% 112% 5%
Net Profit	1.77 1.77	105% 105% 2%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Genfit SA Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

11 days ago

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27....

Neutral

GlobeNewsWire

●

about one month ago

GENFIT Reports First Quarter 2025 Financial Information

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three months of 2025.1

Neutral

GlobeNewsWire

●

about one month ago

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen's Iqirvo®1 has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC).

More Genfit SA Sponsored ADR News

Company Profile

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.

Head office	France
CEO	Mr. Prigent
Employees	169
Founded	1999
Website	www.genfit.fr

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now